ABBV · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

AbbVie Inc. · 2026-11-03 · Importance 54 · Surprise 40 · No source text

Worldwide net revenues for the nine months ended September 30, 2026 were $49.396 billion, up 10.9% reported and 10.1% at constant currency; U.S. revenue rose 9.9% to $37.163 billion and international revenue rose 14.0% to $12.233 billion. Skyrizi revenue increased 25.6% to $15.764 billion and Rinvoq increased 23.9% to $7.350 billion, while Humira fell 35.4% to $2.127 billion following biosimilar competition. Neuroscience growth included Qulipta up 39.6% to $1.044 billion, Ubrelvy up 26.7% to $1.180 billion, and Vraylar up 17.1% to $3.044 billion; Imbruvica declined 26.8% to $1.610 billion. Other notable changes included Elahere growth of 24.5%, Juvederm Collection decline of 6.0%, and Mavyret decline of 8.3% for the nine-month period.

Key facts

• For the nine months ended September 30, 2026, AbbVie reported worldwide net revenues of $49.4 billion, operating earnings of $16.7 billion, diluted earnings per share of $4.79, and operating cash flows of $14.9 billion; worldwide net revenues increased 11% reported and 10% constant currency. source

Impact estimates